The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the annual infectious diseases meeting of the American Society for Microbiology. This webpage will broadcast the daily press conferences for the 50th ICAAC being held September 12-15, 2010 at the Boston Convention and Exhibition Center. For more information about ICAAC please visit www.icaac.org. If you are a member of the press visit the ICAAC newsroom.
[ustream asm-live] [uschat asm-live 416 340]
(To ask a question please post it in the chat or tweet @microbeworld. You can also use the hash tag #ICAAC)
Please note: The following schedule is preliminary and subject to change. Participants and more detail for each conference will be posted soon. All participants are invited, not confirmed.
Sunday, September 12
WATCH 12:00 noon EDT – Opening Briefing
Members of the ICAAC Program Committee will give an overview of the ICAAC meeting and discuss sessions of particular interest. Lunch will follow.
WATCH 1:00 p.m., EDT – What Big Pharma Wants and What Small Biotech Can Offer
- M. Lindsay Grayson, Austin Hospital/Austin Health, Melbourne, Australia
- Craig Rubens, Children’s Hospital & Regional Medical Center, Seattle, WA
- Karen Bush, Indiana University, Bloomington, IN
- Laurent Kaiser, University Hospitals of Geneva, Geneva, Switzerland
As larger pharmaceutical companies have reduced focus on discovery and early development of antibacterials, smaller biotech companies have taken on a larger role in these earliest stages of antibacterial development, later licensing or selling the compound to the pharmaceutical company to complete development. Although this model has helped to partially resuscitate a diminishing antibacterial pipeline, is it the most effective model for the development of new drugs? Participants will outline the advantages and pitfalls associated with this model as well as other proposed models for drug development and will also discuss what new drugs are currently in this pipeline.
WATCH 2:00 p.m., EDT – Antimicrobial-Resistant Pathogens: An Emerging Pediatric Threat
- Gary Noel, Johnson and Johnson, North Caldwell, NJ, United States
- Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria
Antibiotic resistance has become an increasing cause for concern around the globe, but it poses a unique set of problems for infections in children. Researchers will present the latest information on antibiotic-resistant infections of concern to pediatricians including methicillin-resistant Staphylococcus aureus (MRSA), other extended-spectrum beta lactamase-producing (ESBL) bacteria (so-called superbugs) and drug-resistant infections in children with cystic fibrosis.
- Anne Blaschke, Univeristy of Utah, Salt Lake City, UT, United States
- S. Elliott, Steele Children's Research Center, Tucson, AZ, United States
Monday, September 13
WATCH 10:00 a.m., EDT – NDM-1: The New Superbugs
New Dehli metallo-beta-lactamase-1 (NDM-1) is an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics. These include the antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infections. According the the United Kingdom’s health protection agency, most bacteria carrying the gene for NDM-1 are resistant to all standard intravenous antibiotic treatments for severe infections. First identified in a patient in New Dehli in December 2009, the NDM-1 gene has since been found in infections in the United States, the United Kingdom and Canada. Participants will discuss the growing global threat of NDM-1 as well as late-breaker abstracts describing cases in the U.S. and Canada.
- Patrice Nordmann, Hosp. Bicetre, La Kremlin-Bicetre, France
- Timothy Walsh, Cardiff University, Cardiff, United Kingdom
- Johann Pitout, University of Calgary, Alberta, Canada
WATCH 11:15 a.m. EDT – Handwashing Survey Results
Mom's advice about cleaning your hands may finally be starting to get through. In the August 2010 observational study sponsored by the American Society for Microbiology and the American Cleaning Institute® (formerly The Soap and Detergent Association), 85% of adults washed their hands in public restrooms, compared with 77% in 2007. The 85% total was actually the highest observed since these studies began in 1996.
- Barbara Hyde, Director of Communications, American Society for Microbiology, Washington, D.C.
- Didier Pettit, Director, Infection Control Program, University of Geneva, Hospital, Switzerland
- Judy Daly, Professor of Pathology, University of Utah
WATCH 12:00 noon EDT – Emerging Issues in Infectious Disease
Participants in this session will discuss the latest issues appearing on the horizon for infectious disease researchers including the changing epidemiology of drug resistance in Salmonella, epidemiology and management of extensively drug-resistant (XDR) tuberculosis and the possibility that chronic fatigue syndrome could be associated with a retroviral infection.
- Myra McClure, Imperial College London, United Kingdom
- John Crump, Duke University Medical Center, Durham, NC, United States
WATCH 1:15 p.m., EDT – A Role for Statins in Infectious Disease?
Statins are well-known as a class of drugs that are used to help lower cholesterol but recent evidence suggests they might be good for more than your heart. They may play a role in preventing and treating certain bacterial infections including pneumonia and sepsis. Presenters will discuss the latest research on the potential of these drugs.
- Reimar Thomsen, Aarhus University Hospital, Aalborg, Denmark
- Matthew Falagas, Alfa Institute of Biomedical Sciences, Athens, Greece
- Nasia Safdar, University of Wisconsin, Madison, WI, United States
Tuesday, September 14
WATCH 10:00 a.m., EDT – Community-associated MRSA: Why is it spreading so quickly?
Methicillin-resistant Staphylococcus aureus (MRSA) was discovered in 1960. Over the following 40 years, MRSA was a problem confined largely to the health-care setting. In the late 1990s, the first United States reports of community-associated MRSA (CA-MRSA) infections appeared. At present, several reports suggest that CA-MRSA may be replacing the hospital-associated MRSA strains with potentially catastrophic consequences. Presenters will discuss the latest research on our understanding of CA-MRSA, why it is spreading across the globe so quickly and what, if anything, can be done about it.
WATCH 11:00 a.m., EDT – Is the Era of Bacterial Culture Ending?
- Henry Chambers, UCSF, San Francisco, CA, United States
- Matteo Bassetti, San Martino Hospital, Genova, Italy
- Michael Otto, NIH, NIAID, Bethesda, MD, United States
As technology continues to move forward, fast DNA-based tests can offer diagnosis in hours compared to the days it can take for a bacterial culture to grow, often with the same level of certainty. Still, cultures remain the definitive gold-standard for confirming diagnosis. Have we finally reached the point technologically where physicians no longer have to rely on cultures for diagnosing bacterial infections?
WATCH 1:00 p.m., EDT – Weird Bugs, Weird Places: The Microbial Risks of Taking a Shower
- Patricia Muñoz, Hospital Univ. Gregorio Marañón, Madrid, Spain
- Jacques Schrenzel, Geneva University Hospitals, Geneva, Switzerland
- Donna Wolk, University of Arizona, Tucson, AZ, United States
- Mark Krockenberger, University of Syndey, New South Wales, Australia
- Daniel Frank, University of Colorado, Boulder, CO, United States
- Paul Johnson, Austin Health, Melbourne, Australia